Christophe Arbet-Engels - 13 Feb 2024 Form 4/A Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Role
Chief Medical Officer
Signature
/s/ Adam S. Mostafa, attorney-in-fact
Issuer symbol
XFOR
Transactions as of
13 Feb 2024
Net transactions value
$0
Form type
4/A
Filing time
28 Feb 2024, 17:52:37 UTC
Date Of Original Report
16 Feb 2024
Previous filing
05 Sep 2023
Next filing
27 Jan 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XFOR Stock Appreciation Right Award $0 +180,816 $0.000000 180,816 13 Feb 2024 Common Stock 180,816 $0.9210 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Form 4 amendment is being filed to correct the number of stock appreciation rights awarded to the Reporting Person on February 13, 2024. The original Form 4 filed on February 16, 2024 inadvertently reported the number of stock appreciation rights awarded as 475,831 due to an administrative error.
F2 The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date.